Skip to main content
Genomed Spolka Akcyjna logo

Genomed Spolka Akcyjna — Investor Relations & Filings

Ticker · GEN ISIN · PLGNOMD00024 LEI · 259400MZZJNF1JFWAG26 WAR Professional, scientific and technical activities
Open in API
Filings indexed 262 across all filing types
Latest filing 2026-05-29 AGM Information
Country PL Poland
Listing WAR GEN

About Genomed Spolka Akcyjna

http://www.genomed.pl

Genomed Spolka Akcyjna is a biotechnology company specializing in genetic research and molecular diagnostics. It offers a comprehensive range of services centered on DNA and RNA sequencing, analysis, and synthesis, primarily utilizing Next Generation Sequencing (NGS) technology. The company's core activities include the analysis of gene sequences to identify mutations responsible for congenital diseases, with the capability to analyze thousands of genes. Genomed serves both the clinical diagnostics and research sectors, providing services to the medical and biotechnological markets. A key strategic focus is the development and introduction of genomic technologies into personalized medicine, aiming to advance genomic prevention and gene treatments in medical practice.

Recent filings

Filing Released Lang Actions
Projekty Uchwał
AGM Information Classification · 95% confidence The document is a set of draft resolutions (projekty uchwał) for the Ordinary General Meeting of Genomed S.A. scheduled for June 30, 2026. It contains agenda items and proposed shareholder resolutions (election of chairman, approval of reports and financial statements, profit distribution, discharge of duties, amendments to the statutes, etc.). This is clearly part of the materials provided to shareholders for the AGM rather than an annual report, financial statements, proxy statement with recommendations, or any other regulatory or financial filing. Therefore, it should be classified as AGM Information (AGM-R).
2026-05-29 Polish
Ogłoszenie o zwołaniu WZA
AGM Information Classification · 85% confidence The document is a Polish “Ogłoszenie o zwołaniu Zwyczajnego Walnego Zgromadzenia” (notice of convening the Ordinary General Meeting of Shareholders). It sets out the date, place, agenda, registration date, and shareholder rights related to the AGM. It is not the actual minutes, results, financial statements, nor a management discussion—it is purely an AGM convening notice. The closest match in our taxonomy is AGM Information (Code: AGM-R), which covers materials related to the AGM, including notices and agendas.
2026-05-29 Polish
Zwołanie Zwyczajnego Walnego Zgromadzenia Akcjonariuszy GENOMED S.A. - Content (PL)
Proxy Solicitation & Information Statement Classification · 85% confidence The text is an announcement from the management board convening the Ordinary General Meeting (ZWZ) with draft resolutions and proxy forms. This constitutes materials sent to shareholders to provide information and request votes for an upcoming meeting, fitting the Proxy Solicitation & Information Statement category.
2026-05-29 Polish
Diagnostyka_Akcje
Director's Dealing Classification · 100% confidence The document is a formal notification of a transaction in financial instruments (shares) by a person closely associated with a person discharging managerial responsibilities (PDMR). It explicitly references Article 19(1) of the Market Abuse Regulation (MAR). This is a standard disclosure form for insider dealings or transactions by persons closely associated with management, which falls under the 'Director's Dealing' category.
2025-12-22 Polish
Powiadomienie o transakcjach na akcjach Spółki - Content (PL)
Director's Dealing Classification · 95% confidence The document is a short notification (297 characters) from Genomed S.A. regarding a transaction on its shares by a major shareholder (Diagnostyka SA). It explicitly states that the full notification is in the attachment. This fits the definition of a Major Shareholding Notification (MRQ) as it concerns a transaction notification by a significant entity, and follows the 'Menu vs Meal' rule by acting as an announcement of the underlying disclosure.
2025-12-22 Polish
Rekomendacja dotycząca podziału zysku Spółki za rok 2024 - Content (PL)
Transaction in Own Shares Classification · 98% confidence The document text, written in Polish, discusses a decision by the Management Board (Zarząd) of Genomed S.A. to propose to the upcoming Annual General Meeting (Zwyczajnemu Walnemu Zgromadzeniu) the allocation of the entire 2024 profit (1,105,239.10 PLN) to the reserve capital for the purpose of acquiring own shares (nabycia akcji własnych). This directly relates to the company's intention to repurchase its own stock. The most specific category for reporting the company buying back or selling its own shares is 'Transaction in Own Shares' (POS). Although it mentions the AGM, the core subject is the proposed use of profit for share repurchase, not the AGM agenda itself (AGM-R) or a general capital change (CAP). Given the short length and specific content, POS is the best fit.
2025-06-13 Polish

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.